Please enable JavaScript.
Coggle requires JavaScript to display documents.
Research Article - Coggle Diagram
Research Article
conclusions
-
any advese events similar in both groups, but more serious events more likley in placebo group
-
-
results consistent between age, sex, location, and preexisting conditions
-
experiment
treatment within 3 days of onset of symptoms, assessment after 28 days
"trial evalutaed the efficacy, viral load, and safety associated with the use on nirmatrelvir plus ritonavir
-
patients were symptomatic, unvaccinated, nonhospitalized adults
-
results
-
adverse events
serious events:1.6% nirmatrelvir, 6.6% placebo
events leading to discontinuation of treatment: 2.1% nirmatrelvir, 4.2% placebo
any event: 22.6% nirmatrelvir, 23.9% placebo
13 deaths in placebo group, 0 deaths in nirmatrelvir group